Tengshengbok Pharmaceutical-B (02137): Tengshengbok Pharmaceutical has not yet reached a settlement with Vir regarding the claim.

Wisdom Financial News APP News, Tengsheng Boyao-B (02137) announced that on May 23, 2018, the company, Tengsheng Boyao's Cayman subsidiary (a subsidiary of the company, collectively referred to as Tengsheng Boyao) and Vir Biotechnology, Inc. (Vir, a company registered in Delaware, USA, and operating in San Francisco, California) signed a cooperation, option and license agreement (cooperation agreement). According to the agreement, all parties may exercise their options to obtain exclusive licenses to promote the development and commercialization of certain products originally developed by the other party.